Face-to-Face: Trophos looks to nourish ALS market with olesoxime
This article was originally published in Scrip
Executive Summary
At last year's Bio-Europe Spring conference, Trophos's CEO Dr Damian Marron told Scrip that the French company had high hopes for its lead product TRO19622 (olesoxime) in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy. Nine months later he spoke to Simon Varcoe about how those hopes were transpiring.